1. Scrip
  2. >>Business
  3. >>Strategy

Bayer Boss Rules Out Divisions Split For Now

 
• By Kevin Grogan

CEO Bill Anderson says that while the troubled Leverkusen-headquartered group operates three healthy businesses, it has been "badly broken in four places.”

pill
• Source: Bayer

Investors who have been pushing for Bayer AG to break its three-pillar structure of pharmaceuticals, consumer health and crop science will have to wait for a couple more years at least, as CEO Bill Anderson tells journalists that the firm's pipeline, debt, legal and bureaucracy problems need fixing first.

Speaking at the German group's annual results conference in London, Anderson noted that Bayer had "seriously considered the structure of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Ipsen Boosts Cancer Pipeline With ImCheck Buy

 
• By Kevin Grogan

The Paris-based group is paying €350m upfront to get hold of Marseille-headquartered ImCheck's acute myeloid leukemia candidate.

How To Score A Win With Real-World Evidence In India

 
• By Vibha Ravi

Bharat Serums showed it’s possible to score a regulatory win with real-world evidence (RWE) studies in India when it ran one leading to a label expansion for its mAb trinbelimab. As cell and gene therapies and rare disease drugs gain currency, sponsors could look at takeaways from the RhYTHM study.

Failing to Clinch Sale, Galapagos To Wind Down Cell Therapy Business

 
• By Manas Mishra

Galapagos is closing its cell therapy business after a prolonged search for buyers, leading to job cuts and site closures in the US, Netherlands, Switzerland and China.

China’s Next Wave Is First-In-Class Innovation

 
• By Jessica Merrill

Drug development in China was a discussion topic at the BioFuture conference as the country’s R&D investments begin to deliver first-in-class medicines.

More from Business

China’s Next Wave Is First-In-Class Innovation

 
• By Jessica Merrill

Drug development in China was a discussion topic at the BioFuture conference as the country’s R&D investments begin to deliver first-in-class medicines.

Stock Watch: J&J’s $5bn Product Predictions Meet Investor Skepticism

 
• By Andy Smith

Despite announcing sales growth that is currently weathering the storm of one of its biggest losses of exclusivity and a spin-off of its orthopedic division, J&J’s stock price weakened after its earnings announcement. Investors probably wanted more visibility on MFN.

Investors Show Faith In Faeth’s Cancer Metabolism Strategy As Data Read Out At ESMO

 
• By Mandy Jackson

Faeth Therapeutics raised $25m to complete a Phase II trial of its PIK3/mTOR-targeting drug combination in endometrial cancer and reported positive Phase II data at ESMO in ovarian cancer with half of the combo.